Mean (SD) change in PD20AMP, FEV1, and morning and evening PEFR and median (interquartile range) days and nights free of symptoms and bronchodilator use for all three dosing regimens
| 1 week sequential regimen | 2 week sequential regimen | Non-sequential regimen | ||||||
|---|---|---|---|---|---|---|---|---|
| 100 μg | 400 μg | 1600 μg | 100 μg | 400 μg | 1600 μg | 1600 μg 1 week | 1600 μg 2 weeks | |
| DD = doubling doses; FEV1 = forced expiratory volume in 1 second; PD20AMP = provocative dose of adenosine monophosphate causing a 20% fall in FEV1; PEFR = peak expiratory flow rate; BD = bronchodilator. | ||||||||
| ΔPD20AMP (DD) | 1.49 (1.30) | 2.04 (1.74) | 3.10 (2.53) | 1.96 (1.53) | 2.71 (1.80) | 4.03 (2.51) | 2.14 (1.99) | 3.70 (2.60) |
| ΔFEV1 (ml) | −14 (192) | 77 (226) | 90 (243) | 50 (367) | 124 (242) | 148 (228) | 113 (250) | 81 (252) |
| am PEFR (l/min) | 470 (88.3) | 483 (83.3) | 490 (87.5) | 483 (89.2) | 483 (91.8) | 483 (92.8) | 484 (94.4) | 488 (88.9) |
| pm PEFR (l/min) | 480 (91.5) | 478 (93.9) | 489 (89.7) | 487 (91.6) | 481 (94.2) | 480 (96.5) | 480 (92.7) | 490 (89.2) |
| Symptom free nights (%) | 100 (71–100) | 100 (86–100) | 100 (100–100) | 100 (71–100) | 100 (79–100) | 100 (86–100) | 100 (77–100) | 100 (100–100) |
| Symptom free days (%) | 100 (64–100) | 100 (64–100) | 100 (69–100) | 100 (54–100) | 100 (74–100) | 100 (84–100) | 86 (60–100) | 100 (57–100) |
| BD free nights (%) | 100 (100–100) | 100 (100–100) | 100 (100–100) | 100 (89–100) | 100 (100–100) | 100 (100–100) | 100 (86100) | 100 (100–100) |
| BD free days (%) | 100 (71–100) | 100 (93–100) | 100 (77–100) | 100 (39–100) | 100 (81–100) | 100 (83–100) | 100 (69–100) | 100 (85–100) |